Skip directly to Accessibility Notice

How to Purchase

Sign-up to Receive
Our Latest Insights

BBH
VanEck Vectors Biotech ETF

Fund Description

VanEck Vectors® Biotech ETF (BBH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Biotech 25 Index (MVBBHTR), which is intended to track the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment.

 
 

  • Fund Ticker

    BBH
  • Exchange

    NASDAQ
  • Commencement

    12/20/2011
  • ETF Structure

    Physical
  • Administrator

    Van Eck Associates
  • Custodian

    Bank of New York Mellon
  • Index Ticker

    MVBBHTR
  • Index Rebalancing

    Quarterly

 
as of 09/20/19

  • 30-Day SEC Yield1

    0.42%
  • Total Net Assets

    $340.2M
  • Number of Holdings

    25
  • Options

    Available
  • Gross Expense Ratio2

    0.40%
  • Net Expense Ratio/TER2

    0.35%
  • Distribution Frequency

    Annual
  • Next Distribution Date

    12/20/2019

Key Points

Highly Liquid Companies 
Index seeks to track the most liquid companies in the industry based on market cap and trading volume
Industry Leaders 
Index methodology favors the largest companies in the industry
Global Scope 
Portfolio may include both domestic and U.S. listed foreign companies allowing for enhanced industry representation

Trading Information

  • Fund Ticker

    BBH
  • Index Total Return Ticker

    MVBBHTR
  • NAV

    BBHNV
  • Intraday NAV (IIV)4

    BBHIV
  • Shares Outstanding

    2,746,503
  • Estimated Cash

    BBHEU
  • Total Cash

    BBHTC
  • CUSIP

    92189F726
  • ISIN

    US92189F7261
Source: Bloomberg

Fees and Expenses2

  • Management Fee

    0.35%
  • Other Expenses

    0.05%
  • Gross Expense Ratio

    0.40%
  • Fee Waivers and
    Expense Reimbursement

    -0.05%
  • Net Expense Ratio/TER2

    0.35%
2Expenses for BBH are capped contractually at 0.35% until February 1, 2020. Cap excludes acquired fund fees and expenses, interest expense, trading expenses, taxes and extraordinary expenses.

Prices as of 09/20/19

NAV/
Last Price
Volume
30-Day Avg./
Last Trading Day
Daily Change
NAV/
Last Price
YTD Change
NAV/
Last Price
Premium/
Discount
Prem/Discount
Distribution Charts
NAV &
Prem/Discount
History
NAV
Chart
BBH $123.88
$123.70
13,115
9,139
$0.99 / +0.80%
$0.92 / +0.75%
+11.27%
+11.72%
$-0.18
-0.15%

Performance History: Average Annual Total Returns* (%)

1 MO 3 MO YTD 1 YR 3 YR 5 YR 10 YR LIFE
12/20/11
BBH (NAV) -2.33 5.80 10.68 -8.37 3.17 3.18 -- 17.94
BBH (Share Price) -2.45 5.64 11.15 -8.51 3.14 3.16 -- 17.93
MVBBHTR (Index) -2.33 5.85 10.82 -8.17 3.37 3.36 -- 18.15
Performance Differential (NAV - Index) 0.00 -0.05 -0.14 -0.20 -0.20 -0.18 -- -0.21
1 MO 3 MO YTD 1 YR 3 YR 5 YR 10 YR LIFE
12/20/11
BBH (NAV) 11.07 0.68 16.19 8.38 8.58 6.62 -- 19.14
BBH (Share Price) 10.71 0.37 16.48 8.03 8.50 6.56 -- 19.11
MVBBHTR (Index) 11.08 0.74 16.29 8.62 8.79 6.82 -- 19.35
Performance Differential (NAV - Index) -0.01 -0.06 -0.10 -0.24 -0.21 -0.20 -- -0.21

Top 10 Holdings (%) as of 08/31/19 Daily Holdings

Total Holdings: 25
Swipe
to view
full data
Holding Name
Ticker
Shares Market Value
(US$)
% of Net
Assets
Amgen Inc
AMGN US
186,536
38,915,140 11.29
Gilead Sciences Inc
GILD US
410,481
26,081,963 7.57
Celgene Corp
CELG US
254,632
24,648,378 7.15
Allergan Plc
AGN US
138,635
22,142,782 6.43
Iqvia Holdings Inc
IQV US
121,165
18,798,750 5.46
Vertex Pharmaceuticals Inc
VRTX US
99,343
17,883,727 5.19
Incyte Corp
INCY US
201,264
16,467,420 4.78
Exact Sciences Corp
EXAS US
135,874
16,198,898 4.70
Biogen Inc
BIIB US
73,562
16,165,250 4.69
Beigene Ltd
BGNE US
108,613
15,613,119 4.53
Top 10 Total (%) 61.79
These are not recommendations to buy or to sell any security. Securities and holdings may vary.

Country Weightings (%) as of 08/31/19

  • Country

    % of Net Assets
  • United States

    92.85
  • China

    4.53
  • Spain

    2.62
  • Other/Cash

    -0.01

Sector Weightings (%) as of 08/31/19

  • Sector

    % of Net Assets
  • Health Care

    100.0
  • Other/Cash

    0.0